News & Analysis on Pharmaceutical Technology & Manufacturing
Valeant - Howard Schiller
By Dan Stanton
- Last updated on
First up and Valeant’s CEO J. Michael Pearson (pictured right) is being treated for severe pneumonia and has taken a medical leave of absence until further notice.
As it is uncertain when he is to return, current CFO Howard Schiller (left) is stepping up to take the reins on an interim basis.
“Howard's performance as Valeant's CFO, as well as his deep understanding of Valeant's operations, are excellent and we are grateful that he has agreed to take on this role,” said Robert Ingram, Lead Independent Director, himself set to serve as interim chairman of the Board.
“We appreciate the expressions of support and concern for Mike's health that we have received from Valeant's investors, employees, business partners and other stakeholders. While Mike's illness was sudden and unexpected, our strong management team has stepped in to keep our businesses on track and thriving.”